Fig. 3From: Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expressionBinimetinib inhibits RAS/MAPK pathway activity. Neuroblastoma cells were treated with 1 μM binimetinib for 1 h and then lysed and Western blots for total MEK, phospho-MEK (p-MEK), total ERK, and phospho-ERK (p-ERK) were performed. Actin was used as a loading controlBack to article page